A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus

Overview

Journal Stem Cell Reports

Publisher Cell Press

Specialty Cell Biology

Date 2018 Feb 27

PMID 29478901

Citations 49

Authors

Dandan Wang

Huayong Zhang

Jun Liang

Hong Wang

Bingzhu Hua

Xuebing Feng

Gary S Gilkeson

Dominique Farge

Songtao Shi

Lingyun Sun

Affiliations

Soon will be listed here.

Abstract

Allogeneic mesenchymal stem/stromal cells (MSCs) have been widely studied as an alternative cell source for regenerative medicine. Here, we report a long-term follow-up study of allogeneic bone marrow and/or umbilical cord MSC transplantation (MSCT) in severe and drug-refractory systemic lupus erythematosus (SLE) patients. Eighty-one patients were enrolled, and the 5-year overall survival rate was 84% (68/81) after MSCT. At 5-year follow-up, 27% of patients (22/81) were in complete clinical remission and another 7% (6/81) were in partial clinical remission, with a 5-year disease remission rate of 34% (28/81). In total, 37 patients had achieved clinical remission and then 9 patients subsequently relapsed, with 5-year overall rate of relapse of 24% (9/37). SLE Disease Activity Index scores, serum albumin, complement C3, peripheral white blood cell, and platelet numbers, as well as proteinuria levels, continued to improve during the follow-up. Our results demonstrated that allogeneic MSCT is safe and resulted in long-term clinical remission in SLE patients.

Citing Articles

Host FSTL1 defines the impact of stem cell therapy on liver fibrosis by potentiating the early recruitment of inflammatory macrophages.

Zheng X, Tian S, Li T, Zhang S, Zhou X, Liu Y Signal Transduct Target Ther. 2025; 10(1):81.

PMID: 40050288 PMC: 11885662. DOI: 10.1038/s41392-025-02162-6.

Unveiling distinctions between mesenchymal stromal cells and stem cells by single-cell transcriptomic analysis.

Yan K, Ma F, Song X, Wang H, Liu P, Zhang J Heliyon. 2025; 11(4):e42311.

PMID: 40034318 PMC: 11872483. DOI: 10.1016/j.heliyon.2025.e42311.

Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials.

Zeng L, Liu C, Wu Y, Liu S, Zheng Y, Hao W Stem Cell Res Ther. 2025; 16(1):65.

PMID: 39934871 PMC: 11817852. DOI: 10.1186/s13287-025-04184-x.

Tumor Necrosis Factor Receptor 1 Is Required for Human Umbilical Cord-Derived Mesenchymal Stem Cell-Mediated Rheumatoid Arthritis Therapy.

Liu G, Wang H, Zhang C, Li X, Mi Y, Chen Y Cell Transplant. 2025; 34():9636897241301703.

PMID: 39831589 PMC: 11748158. DOI: 10.1177/09636897241301703.

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus.

Karmakar A, Kumar U, Prabhu S, Ravindran V, Nagaraju S, Suryakanth V Clin Exp Med. 2024; 24(1):223.

PMID: 39294397 PMC: 11410857. DOI: 10.1007/s10238-024-01484-z.

References

Wang D, Zhang H, Liang J, Li X, Feng X, Wang H . Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 2014; 22(12):2267-77. PMC: 11849135. DOI: 10.3727/096368911X582769c. View

Traynor A, Barr W, Rosa R, Rodriguez J, Oyama Y, Baker S . Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum. 2002; 46(11):2917-23. DOI: 10.1002/art.10594. View

Lisnevskaia L, Murphy G, Isenberg D . Systemic lupus erythematosus. Lancet. 2014; 384(9957):1878-1888. DOI: 10.1016/S0140-6736(14)60128-8. View

Relle M, Weinmann-Menke J, Scorletti E, Cavagna L, Schwarting A . Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmun Rev. 2015; 14(11):1005-18. DOI: 10.1016/j.autrev.2015.07.003. View

Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y . Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol. 2009; 5(6):417-24. PMC: 4072411. DOI: 10.1038/cmi.2008.52. View

Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008; 371(9624):1579-86. DOI: 10.1016/S0140-6736(08)60690-X. View

Wang D, Zhang H, Cao M, Tang Y, Liang J, Feng X . Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011; 70(7):1285-8. DOI: 10.1136/ard.2010.141804. View

Alchi B, Jayne D, Labopin M, Demin A, Sergeevicheva V, Alexander T . Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus. 2012; 22(3):245-53. DOI: 10.1177/0961203312470729. View

Wang D, Sun L . Stem cell therapies for systemic lupus erythematosus: current progress and established evidence. Expert Rev Clin Immunol. 2015; 11(6):763-9. DOI: 10.1586/1744666X.2015.1037741. View

10.

Baydar D, Himmetoglu C, Yazici S, Kiziloz H, Ozen H . Primary osteosarcoma of the urinary bladder following cyclophosphamide therapy for systemic lupus erythematosus: a case report. J Med Case Rep. 2009; 3:39. PMC: 2642852. DOI: 10.1186/1752-1947-3-39. View

11.

Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T . Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell. 2012; 10(5):544-55. PMC: 3348385. DOI: 10.1016/j.stem.2012.03.007. View

12.

Shi D, Wang D, Li X, Zhang H, Che N, Lu Z . Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus. Clin Rheumatol. 2012; 31(5):841-6. DOI: 10.1007/s10067-012-1943-2. View

13.

Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X . Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014; 16(2):R79. PMC: 4060570. DOI: 10.1186/ar4520. View

14.

Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H . Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010; 62(8):2467-75. DOI: 10.1002/art.27548. View

15.

Murphy G, Lisnevskaia L, Isenberg D . Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet. 2013; 382(9894):809-18. DOI: 10.1016/S0140-6736(13)60889-2. View

16.

Xu J, Wang D, Liu D, Fan Z, Zhang H, Liu O . Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood. 2012; 120(15):3142-51. PMC: 3471521. DOI: 10.1182/blood-2011-11-391144. View

17.

Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S . Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010; 69(8):1423-9. DOI: 10.1136/ard.2009.123463. View

18.

Burt R, Traynor A, Statkute L, Barr W, Rosa R, Schroeder J . Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006; 295(5):527-35. DOI: 10.1001/jama.295.5.527. View

19.

Lalu M, McIntyre L, Pugliese C, Fergusson D, Winston B, Marshall J . Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012; 7(10):e47559. PMC: 3485008. DOI: 10.1371/journal.pone.0047559. View

20.

Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R . Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004; 13(3):168-76. DOI: 10.1191/0961203304lu525oa. View